AzTrials
AzTrials

Covid19NCT04853316

Asymptomatic SARS-CoV-2 Detection in Children

An observational study of Covid19 and SARS-CoV-2, run by University of Calgary at 5 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of this study is quantify the transmission risk posted by SARS-CoV-2 in pre/asymptomatic infected children in order to inform the public health response to the COVID-19 pandemic. Read more about this study

Who is it for?
Ages Up to 18 years
Conditions the study is for
Covid19, SARS-CoV-2
How many people
372 participants
Where
5 sitesin 2 countries
Study dates
31 Jan 2021to 22 Aug 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: All children younger than 18 years of age presenting to a participating ED who meet institutional surveillance screening guidelines (i.e. present with a non-infectious, non-viral concern) and undergo SARS-CoV-2 testing. The number of children eligible may vary based on evolving SARS-CoV-2 testing procedures, public health policy, and patient volumes.

Who may be able to join

  • Younger than 18 years of age
  • Had SARS-CoV-2 NAT testing performed during the ED visit as part of an ongoing active asymptomatic surveillance program:
  • Exposed (SARS-CoV-2 positive) specific: Was found positive by SARS-CoV-2 NAT testing in the ongoing active surveillance program
  • Unexposed (SARS-CoV-2 negative/control) specific: Was found negative by SARS-CoV-2 NAT testing in the ongoing active surveillance program

Who cannot join

  • Presence of any of the following viral symptoms commonly associated with SARS-CoV- 2 infection: fever, cough, dyspnea/difficulty breathing, generalized fatigue/weakness, myalgia (muscle or body aches), chills, feeling very unwell, sore throat, runny nose, gastrointestinal symptoms (vomiting, diarrhea), conjunctivitis, headache, anosmia (loss of smell), ageusia (loss of taste) or rash in the 24 hours preceding the index visit (when the child was tested for the presence of SARS-CoV-2).
  • Previously diagnosed with SARS-CoV-2 infection based on a positive swab or serology (blood) test.
  • Decline to provide informed consent and/or assent, as required

Trial locations and contacts

5 sites in 2 countries.

5 sites in 2 countries

United States4 sites
  • Children's of Alabama

    Birmingham, Alabama, 35233

  • Boston Children's Hospital

    Boston, Massachusetts, 02115

  • Children's Medical Center of Dallas - UT Southwestern

    Dallas, Texas, 75235

  • University of California, San Diego - Rady Children's Hospital

    San Diego, California, 92123

Other trials in United States

Canada1 site
  • Alberta Children's Hospital

    Calgary, Alberta, T3B 6A8

Other trials in Canada

About this study

Official title: Household Transmission Dynamics and Viral Load Among Asymptomatic SARS-CoV-2 Infected Children

The primary objective of this study is quantify the transmission risk posted by SARS-CoV-2 in pre/asymptomatic infected children in order to inform the public health response to the COVID-19 pandemic.

Read the detailed description
  1. Background \& Rationale: Background: Transmission from individuals with pre-symptomatic and asymptomatic (hereafter abbreviated as pre/asymptomatic) SARS-CoV-2 infections is the Achilles' heel of COVID-19 pandemic control1. While pediatric SARS-CoV-2 infection is yet to be fully characterized, and generally children are more likely to experience asymptomatic infection or mild disease compared with adults, severe outcomes are possible. Although person-to-person spread is well described in children, as schools have been closed, the transmission risk in that environment remains unknown. More importantly, the contribution of pre/asymptomatic children to overall transmission of SARS-CoV-2 is unclear with most pediatric cases linked to a symptomatic household member. According to China's National Health Commission, 130 (78%) of 166 new infections identified on April 1, 2020 were asymptomatic. In addition, data from an adult long-term care facility in Washington indicates that symptom-based screening failed to identify a significant proportion of COVID-19 cases. Furthermore, based on RT-PCR cycle threshold values, large quantities of viral RNA were detected in pre/asymptomatic residents, suggesting the potential for transmission regardless of symptoms. Asymptomatic pediatric colonization, while reported, is poorly described. Rationale: SARS-CoV-2 shedding has been noted to occur in minimally symptomatic and asymptomatic infected persons. Children therefore, who appear to more commonly experience mild and asymptomatic infection, may represent a significant risk of household and community transmission. Recommendations for school closures are currently based on assumptions as well as evidence gathered from influenza outbreaks where these measures are known to reduce social contacts and interrupt transmission. School closures, however, disrupt the lives of students and their families and may have negative consequences on child health16. Moreover, COVID-19 transmission modelling studies predict that school closures alone prevent only 2 - 4% of COVID-19-related deaths in the general population, much less than other physical distancing interventions. It should be noted that as school closures were in place before observational studies could begin, the secondary clinical attack rate of pre/asymptomatic children is unknown.
  2. Research Questions \& Objectives: The primary objective of this study is quantify the transmission risk posted by SARS-CoV-2 in pre/asymptomatic infected children in order to inform the public health response to the COVID-19 pandemic by determining the following: If the proportion of household members who develop symptomatic illness over the subsequent 12 days is greater among households of pre/asymptomatic SARS-CoV-2 positive children relative to negative children. Mathematical models will be developed to understand the risks associated with other community transmission settings. In SARS-CoV-2 positive children, if quantitative viral loads differ between those who become symptomatic relative to those who remain asymptomatic and have secondary household cases. Secondary aims of this study include the following: Determining risk factors for SARS-CoV-2 pre/asymptomatic infection in children.
  3. Study Design and Methods:

A prospective cohort study, taking place at multiple institutions throughout the United States and Canada, of children brought to the Emergency Department for care due to a condition or illness unrelated to SARS-CoV-2 infection who are tested as part of ongoing local asymptomatic surveillance programs.

For every SARS-CoV-2-positive asymptomatic child enrolled, three asymptomatic SARS-CoV-2-test negative children will also be recruited.

Any child that is tested for the presence of SARS-CoV-2 who is asymptomatic as part of clinical care, will be potentially eligible for the study. Locally, any child who is tested for the presence of SARS-CoV-2 and who is not displaying any known COVID-19 symptoms will be asked by an Alberta Health Services ED staff member for consent to provide their information to the research team to be contacted about potential participation in the study (consent to contact). Due to testing result timelines and to minimize possible exposure, informed consent/assent will be obtained via telephone and a copy of the consent documentation will be sent via email to the consenting individual, if required. Eligibility for the study based on inclusion and exclusion criteria will be determined over the telephone. Data will be obtained from the participant, their caregiver, and their medical chart, as appropriate. To obtain data related to symptomology, additional medical care, additional testing, and household transmission, a follow up questionnaire will be performed 14 days after the baseline ED visit. If a member of the household is waiting on SARS-CoV-2 testing results at the 14 day follow up time point, an additional call will be made 21 days after the baseline ED visit to obtain SARS-CoV-2 test results. A follow-up call will be performed at 90 days to identify any chronic symptoms that may have developed.

Conditions
Covid19, SARS-CoV-2
Keywords
COVID19, Household transmission, Pediatrics, Asymptomatic, Public health
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04853316
Study groupRoleWhat they receive
Case: Exposed (SARS-CoV-2 positive)Participants found positive by SARS-CoV-2 testing.
Control: Unexposed (SARS-CoV-2 negative)Participants found negative by SARS-CoV-2 testing.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Symptoms of COVID-19 in household members of participating children in the subsequent 14 days following enrollment

    The clinical secondary attack rate (SAR) for households of participating children, which will be compared to generate the relative SAR for households of children with varying case and symptom statuses.

    Measured: 14 days

Secondary outcomes (1)
  1. Viral Load of SARS-CoV-2 in positive children

    The difference in typical viral loads between children of different symptom and case statuses, as well as those with and without clinical secondary cases.

    Measured: 14 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Apr 2021
  2. Study start31 Jan 2021
  3. Primary completion22 Apr 2022
  4. Study completion22 Aug 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
372 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04853316
Sponsor's protocol ID
REB20-0609
Status last verified
Aug 2022
First submitted
16 Apr 2021
Last updated
2 Nov 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Covid19 and SARS-CoV-2, run by University of Calgary at 5 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Symptoms of COVID-19 in household members of participating children in the subsequent 14 days following enrollment (time frame: 14 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2022.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Asymptomatic SARS-CoV-2 Detection in Children | AzTrials